Abstract:Abstract Tumor-associated macrophages (TAM) are known to suppress responses to conventional therapeutics and the presence of TAM is generally related to poor prognosis in various cancers. Therefore, depletion of TAM has been one of the main strategies to break the ceiling of efficacy in cancer treatment. However, to date, TAM depletion strategies have not been successful in clinical trials1. Here, we introduce an approach to target TAM by employing Macrophage Receptor with Collagenous Structure (MARCO), a class A scavenger receptor, as a novel immune checkpoint. Previously, we showed MARCO to be the most upregulated mRNA in murine and human dendritic cells following their uptake of dead tumor cells (TP-DC)2. We also showed ex vivo treatment of TP-DC with anti-MARCO mAb (ED31) led to enhanced anti-tumor responses in vivo3,4. The aim of this current study was to explore whether targeting MARCO using ED31 could improve the efficacy of an immune checkpoint inhibitor in murine models of melanoma. In C57BL/6 mice with B16F10 tumors, adding ED31 to anti-CTLA4 mAb (αCTLA4) resulted in enhanced tumor regression and longer survival (p=0.001, p<0.05 vs αCTLA4 monotherapy; p<0.05, p<0.01 vs ED31 monotherapy, respectively). To explore the immune mechanism of ED31 with αCTLA4, we focused on the tumor microenvironment (TME) by flow cytometry. TME immune-profiling consistently revealed that one time treatment with this combination resulted in a rapid increase in the number of tumor infiltrating lymphocytes (TIL) including CD8+T (2.8-fold) and CD4+T cells (2.9-fold), NK cells (2.5-fold), activated CD11c+DC (2.2-fold) and F4/80+Mφ (2.5-fold), compared to αCTLA4 monotherapy (all with p<0.0001; vs αCTLA4 monotherapy, vs ED31 monotherapy, vs control, respectively). As measured by chemokine production using murine bone marrow-derived, in vitro M-CSF induced Mφ phenotypes (M1: polarized by IFNγ and LPS, M2: polarized by IL4, TAM-like Mφ: polarized by a supernatant from B16F10 cell line culture), ED31 exposure switched the pattern of chemokine productions from M2 and TAM-like Mφ into an M1 pattern. In vivo depletion of each immune cell type had a diminishing effect on the treatment efficacy (p<0.001 for CD8 depletion, p=0.01 for CD4 depletion, p<0.01 for NK1.1 depletion). However, Mφ depletion had a more profound impact by completely abrogating the anti-tumor efficacy and the associated survival benefit, in addition to completely reversing the increase in TIL infiltration and canceling the increase of M1 chemokines in vivo (all with p<0.05 vs Mφ depletion). These preclinical data support the proof-of-concept that a combination strategy of targeting MARCO along with αCTLA4 can lead to enhanced anti-tumor responses through utilizing TAMs rather than their depletion. 1 Immunity 2023;56:2188. 2 J Immunol 2003;171:2879. 3 Cancer Immunol Immunother 2010;59:875. 4 PLoS One 2013;8:e67795. Citation Format: Hidenori Takahashi, Patricio Perez-Villarroel, Rana Falahat, James J. Mulé. Targeting MARCO in combination with anti-CTLA4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3918.

Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway

Blocking CX3CR1+ Tumor-associated Macrophages Enhances the Efficacy of Anti-PD-1 Therapy in Hepatocellular Carcinoma

Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma.

IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer

Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function

Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma

Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress

Abstract 3918: Targeting MARCO in combination with anti-CTLA4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming

PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity

Liver Metastasis Modulate Responses of Suppressive Macrophages and Exhausted T Cells to Immunotherapy Revealed by Single Cell Sequencing

Targeted xCT‐mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti‐PD‐1/L1 Response

Disruption of Tumour-Associated Macrophage Trafficking by the Osteopontin-Induced Colony-Stimulating Factor-1 Signalling Sensitises Hepatocellular Carcinoma to Anti-Pd-l1 Blockade

Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma

Blocking Triggering Receptor Expressed on Myeloid Cells‐1‐Positive Tumor‐Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti‐Programmed Cell Death Ligand 1 Resistance in Liver Cancer

Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma

Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8+ T cells in liver cancer

Synergy of nanodiamond–doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells

Hepatoma Cell-Intrinsic TLR9 Activation Induces Immune Escape Through PD-L1 Upregulation in Hepatocellular Carcinoma

M1‐like tumor‐associated macrophages enhance proliferation and anti‐apoptotic ability of liver cancer cells via activating the NF‐κB signaling pathway

Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing